专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20090035268A1 TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
公开(公告)号：US20090035268A1
公开(公告)日：2009-02-05
申请号：US11832096
申请日：2007-08-01
申请人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D257/04 , A61K31/41 , A61P31/12 , A61K31/7056
CPC分类号： C07K5/0808 , A61K38/21 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters or prodrugs thereof: which can inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

62. 发明授权

US07662779B2 Triazolyl macrocyclic hepatitis C serine protease inhibitors 失效
标题翻译：三唑基大环丙型肝炎丝氨酸蛋白酶抑制剂
公开(公告)号：US07662779B2
公开(公告)日：2010-02-16
申请号：US11835657
申请日：2007-08-08
申请人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Deqiang Niu , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/12 , C07K5/12
CPC分类号： C07D487/04 , A61K31/4192 , A61K31/427 , A61K31/4439 , A61K31/4709 , A61K31/506 , A61K31/5377 , A61K31/7056 , A61K38/21 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
摘要翻译：本发明涉及式I或II的化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过向受试者施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

63. 发明申请

US20090035271A1 TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
公开(公告)号：US20090035271A1
公开(公告)日：2009-02-05
申请号：US11832240
申请日：2007-08-01
申请人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Dong Liu , Yat Sun Or , Zhe Wang
IPC分类号： A61K31/41 , A61K31/407 , A61K31/496 , A61K31/5377 , A61K31/7056 , A61K38/21 , A61P31/12 , C07D245/04
CPC分类号： A61K31/01 , A61K31/407 , A61K31/41 , A61K31/496 , A61K31/5377 , A61K31/7056 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

64. 发明申请

US20080292587A1 OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS 审中-公开
标题翻译： OXIMYL DIPEPTIDE HEPATITIS C蛋白酶抑制剂
公开(公告)号：US20080292587A1
公开(公告)日：2008-11-27
申请号：US12108659
申请日：2008-04-24
申请人： Ying Sun , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/05 , C07D207/12 , C07D409/12 , A61P31/12 , A61K38/21 , C07D405/12
CPC分类号： C07K5/0202 , A61K38/21 , C07K5/06165 , A61K2300/00
摘要： The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明公开了式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

65. 发明申请

US20080286233A1 PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
标题翻译：哌嗪类大环内酯类抗生素C丝氨酸蛋白酶抑制剂
公开(公告)号：US20080286233A1
公开(公告)日：2008-11-20
申请号：US12108639
申请日：2008-04-24
申请人： Ying Sun , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , C07D487/04 , A61P31/12 , A61K38/05
CPC分类号： C07D487/04 , A61K31/551 , A61K38/05 , A61K38/21 , A61K45/06 , A61K2300/00
摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

66. 发明申请

US20080267917A1 N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
标题翻译： N-功能性氨基酸作为丙型肝炎蛋白酶抑制剂
公开(公告)号：US20080267917A1
公开(公告)日：2008-10-30
申请号：US11740502
申请日：2007-04-26
申请人： Deqiang Niu , Joel D. Moore , Dong Liu , Ying Sun , Yat Sun Or , Zhe Wang
发明人： Deqiang Niu , Joel D. Moore , Dong Liu , Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/12 , A61K38/21 , C07K5/08 , A61P31/12 , C07K5/12 , A61K38/06
CPC分类号： C07K5/0812 , A61K38/21 , C07K5/0802 , C07K5/0808 , A61K2300/00
摘要： The present invention relates to functionalized amides of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
摘要翻译：本发明涉及式I或式II的官能化酰胺，其包括抑制丝氨酸蛋白酶活性的药学上可接受的盐，酯或前药，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

67. 发明申请

US20080187516A1 ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS 审中-公开
公开(公告)号：US20080187516A1
公开(公告)日：2008-08-07
申请号：US12016631
申请日：2008-01-18
申请人： Ying Sun , Yat Sun Or , Zhe Wang
发明人： Ying Sun , Yat Sun Or , Zhe Wang
IPC分类号： A61K38/21 , A61K31/4015 , A61P31/12
CPC分类号： C07D487/04 , A61K31/4015 , C07D207/16 , C07K5/0808 , C07K5/0812
摘要： The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

68. 发明申请

US20170003079A1 Systems and Methods of Using Phase Change Material in Power Plants 审中-公开
标题翻译：电厂使用相变材料的系统与方法
公开(公告)号：US20170003079A1
公开(公告)日：2017-01-05
申请号：US15266217
申请日：2016-09-15
申请人： Ying Sun , Matthew McCarthy , Young I. Cho , Philipp Boettcher , Han Hu , Baolan Shi , Qinghua Xie , Kent Zammit
发明人： Ying Sun , Matthew McCarthy , Young I. Cho , Philipp Boettcher , Han Hu , Baolan Shi , Qinghua Xie , Kent Zammit
IPC分类号： F28D1/02 , F28B1/02
CPC分类号： F28D1/024 , F28B1/02 , F28B9/06 , F28C1/14 , F28C3/10 , F28D20/021 , F28D20/023 , F28F2245/04 , Y02E60/145
摘要： Phase change material modules for use in a heat exchanger are described. The phase change material module comprises two or more set of a plurality of substantially aligned hollow structures arranged to form a porous structure. A phase change material capable of undergoing a phase change as a result of heat exchange between it and a fluid is housed within the hollow tubes. Also described is a phase change material module with hollow tubes having a cross-sectional area through the phase change material selected from elliptical, rectangular, stadium-shaped, teardrop-shaped, airfoil-shaped, rounded rectangle and ovoid. A heat exchanger comprising a plurality of the phase change material modules, a first fluid inlet and outlet, and a second fluid inlet and outlet, wherein the phase change material modules are repeated circulated from alignment with the first fluid inlet and the second fluid inlet is also described.
摘要翻译：描述了用于热交换器的相变材料模块。相变材料模块包括布置成形成多孔结构的两组或多组多个基本排列的中空结构。能够由于其与流体之间的热交换而发生相变的相变材料容纳在中空管内。还描述了一种相变材料模块，其具有中空管，该中空管具有穿过相变材料的横截面积，该相变材料选自椭圆形，矩形，体育场形，泪滴形，翼型，圆形矩形和卵形。一种热交换器，其包括多个所述相变材料模块，第一流体入口和出口以及第二流体入口和出口，其中所述相变材料模块与所述第一流体入口对准地重复循环，并且所述第二流体入口是也描述。

69. 发明授权

US09332474B2 Signaling support for multi sector deployment in cellular communications 有权
标题翻译：蜂窝通信中多扇区部署的信令支持
公开(公告)号：US09332474B2
公开(公告)日：2016-05-03
申请号：US13545941
申请日：2012-07-10
申请人： Ying Sun , Tao Cui
发明人： Ying Sun , Tao Cui
IPC分类号： H04W4/00 , H04W36/30 , H04W92/20 , H04W36/02
CPC分类号： H04W36/30 , H04B17/318 , H04W36/023 , H04W92/20
摘要： A method in a controller for a first cell in a mobile cellular network for making a decision to handover a user equipment to a second cell of the mobile cellular network is described. The method may include obtaining a first measurement of an uplink signal from a user equipment at the first cell, obtaining a second measurement of an uplink signal from the user equipment at the second cell, and making a decision to handover the user equipment from the first cell to the second cell using the obtained first and second measurements.
摘要翻译：描述了用于移动蜂窝网络中的第一小区的控制器中的用于做出将用户设备切换到移动蜂窝网络的第二小区的决定的方法。该方法可以包括从第一小区的用户设备获得上行链路信号的第一测量值，从第二小区的用户设备获得上行链路信号的第二测量值，以及从第一小区切换用户设备的决定使用获得的第一和第二测量将单元传送到第二单元。

70. 发明授权

US08949293B2 Automatically matching data sets with storage components 有权
标题翻译：自动将数据集与存储组件进行匹配
公开(公告)号：US08949293B2
公开(公告)日：2015-02-03
申请号：US12972137
申请日：2010-12-17
申请人： Magdi A. Morsi , Wai Ho Au , Ying Sun , Sanjeev Katariya , Yang Xu , Nina Sarawgi
发明人： Magdi A. Morsi , Wai Ho Au , Ying Sun , Sanjeev Katariya , Yang Xu , Nina Sarawgi
IPC分类号： G06F17/30 , G06F11/34
CPC分类号： G06F17/30289 , G06F11/3442 , G06F11/3485
摘要： An administrator of an enterprise storage set may be tasked with storing a large number and variety of data sets on a large number and variety of storage components. However, the manual selection of a physical schema by an administrator may be time-consuming, may generate inefficient physical schemata, and may not be easily reevaluated as the data sets and storage set change. Presented herein are techniques for automatically determining a physical schema by comparing the storage factors of each data set (e.g., data size, relationships with other data sets, and usages of the data set by users) with the storage capabilities of the storage components, selecting a suitable storage component, and implementing the storage of the data set on the storage component. An embodiment of these techniques may thereby achieve an automated identification of a physical schema with improved efficiency and flexibility of the physical schema while conserving administrative resources.
摘要翻译：企业存储集的管理员可以负责在大量和多种存储组件上存储大量和多种数据集。然而，由管理员手动选择物理模式可能是耗时的，可能产生低效的物理模式，并且可能不会随数据集和存储集改变而容易地重新评估。这里提出的技术是通过将每个数据集的存储因子（例如，数据大小，与其他数据集的关系以及用户的数据集的使用）与存储组件的存储能力进行比较来自动确定物理模式，选择合适的存储组件，以及在存储组件上实现数据集的存储。因此，这些技术的实施例可以实现物理模式的自动识别，同时节省管理资源，同时提高物理模式的效率和灵活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式